Title1850.The start
Sir George Grey served as a Governor of the Cape of Good Hope...Read more
Lennon establishes himself
By 1858 the local press were featuring advertisements detailing the Lennon products, which had just arrived by ship and were available in pharmacies.Read more
1884. Advertisement in the first South African Medical Journal
The first issue of the publication...Read more
1898. Lennon Limited is born
By 1898, due to the tremendous expansion...Read more
1899. First annual report
The first annual report noted a satisfactory performance despite...Read more
1911. Lennon is widely established
By 1911, Lennon Ltd...Read more
1930. Lennon – largest in the southern hemisphere
In 1930 Lennon Ltd was the largest pharmaceutical company...Read more
1957. 30 June 1957 financials
During the 1950s and 1960s Lennon Ltd...Read more
1967. The Lennon factory in Port Elizabeth
View from the North End Lake, showing the Welfare Block in the foreground...Read more
1975. Lennon – a generic front runner
The Medicines and Related Substances Act of 1965 prompted most...Read more
1996. SA Druggists
In 1968 the South African Druggists group, including Lennon Ltd, was listed on the Johannesburg Stock Exchange...Read more
1997. Humble beginnings
Stephen Saad and Gus Attridge were two of the four founding members of Aspen...Read more
1998. JSE listing
Aspen was listed on the JSE through reverse listing into Medhold Ltd.Read more
1999. SA Druggists acquired
Aspen acquired South African Druggists, the oldest pharmaceutical business in South Africa...Read more
2001. Aspen Australia opens
Aspen Australia commenced as a start-up operations in Sydney and...Read more
2002. Aspen’s new corporate identity
Aspen’s new corporate identity was launched symbolising energy, innovation and nurturing.Read more
Title2002. CEPPWAWU deal
Aspen concluded a broad-based black economic empowerment deal with...Read more
2003. First generic ARV launched
Aspen Stavudine was launched – Africa’s first generic antiretroviral (ARV).Read more
2004. PE facility construction
Aspen’s state-of-the-art, multi-million Rand oral solid dose...Read more
2004. Fine Chemicals
Aspen acquired Fine Chemicals in Cape Town, the only South African manufacturer of active pharmaceutical ingredients.Read more
2004. Infacare acquisition
Aspen acquired Infacare, the infant nutritional brand, from Dutch-based Royal Numico.Read more
2005. US FDA approval
Aspen’s Unit 1 facility in Port Elizabeth became the world’s first manufacturing facility to receive tentative US FDA approval for the production of certain generic ARVs.Read more
2005. Imithi transaction
Aspen extended its broad-based black economic empowerment ownership through an empowerment transaction with Imithi Investments (Pty) Ltd.Read more
2006. Aspen largest supplier of ARVs in Africa
Aspen was recognised as the largest supplier of ARVs in Africa...Read more
2006. Manufacturing and capacity enhancements
Construction commenced on the Sterile Facility at the Port Elizabeth site.Read more
2008. Aspen enters Latin America
Aspen entered the Latin American market through an investment in businesses established in Brazil, Mexico and Venezuela and...Read more
2008. GSK product acquisition
Aspen acquired the intellectual property rights from GSK for four key global brands: Eltroxin, Imuran, Lanoxin and Zyloric...Read more
2009. Further GSK transactions
Aspen concluded a series of strategic transactions with GSK comprising the acquisition of the rights to distribute GSK’s pharmaceutical products in South Africa...Read more
2011. Aspen expands its Australian presence
Aspen started its business in 2001 with two people. In 2011 Aspen acquired the largest...Read more
2011. Aspen embraces Mandela Day
Aspen joined the call of the Former South African President Nelson Mandela in support of an annual event to benefit disadvantaged communities.Read more
2012. Aspen joins Social Compact
Aspen signalled its support of the Social Compact, as a founder member of the Public Healthcare Enhancement Fund in South Africa...Read more
2013. Expansion of Aspen’s infant nutritional products
2013 heralded Aspen’s acquisition of rights to infant nutritional brands and related businesses from Nestlé in Australia, a number of Latin American territories...Read more
2013. Branded products and API site acquired from MSD
Aspen acquired an API manufacturing business, primarily at Oss in the Netherlands (effective 1 October 2013), and a portfolio of 11 branded finished dose form molecules...Read more
2014. Acquisition of anticoagulants from GSK
Aspen concluded two related transactions with GSK, valued at approximately R12 billion, to acquire the Arixtra and Fraxiparine/Fraxodi thrombolytic brands worldwide...Read more
2014. Aspen goes global
Aspen expanded its global footprint, commencing activity in an additional 21 countries and taking the number of Aspen offices and sites around the world to more than 50.Read more
2015. New global headquarters complete
New global headquarters complete.Read more
2016 - Exclusive Rights to anaesthetics
Acquired the exclisive rights to commercialise AstraZeneca's global anaesthetics portfolio in 100 countries worldwide, including China but excluding the USARead more
Titletest
ContenttestRead more
Ghana-Kama 
Kenya-Beta Healthcare 
Mauritius 
MENAT 
Nigeria 
South Africa-FCC 
South Africa-HOLDINGS 
South Africa-Pharmacare 
Tanzania-Shelys 
Brazil 
Canada 
Mexico 
USA 
China 
Malaysia 
Philippines 
Australia 
New Zealand 
Austria 
France 
Germany 
Netherlands 
Netherlands-Aspen API 
Russia 
SPAIN 
SWITZERLAND